Haemodialysis before emergency surgery in a patient treated with dabigatran

被引:14
作者
Esnault, P. [1 ]
Gaillard, P. E. [1 ]
Cotte, J. [1 ]
Cungi, P. J. [1 ]
Beaume, J. [1 ]
Prunet, B. [1 ]
机构
[1] Mil Teaching Hosp St Anne, Dept Anesthesiol & Intens Care, F-83000 Toulon, France
关键词
dabigatran; haemodialysis; surgery; VENOUS THROMBOEMBOLISM; ETEXILATE; REVERSAL;
D O I
10.1093/bja/aet160
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Novel oral anticoagulants (NOAs) which directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban and apixaban) have recently been developed. We report the first case of perioperative management of a patient treated with dabigatran requiring haemodialysis before emergency surgery. A 62-yr-old woman visited the emergency department for a left bi-malleolar ankle fracture; she had a past medical history of severe ischaemic cardiomyopathy, alcoholic cirrhosis Child B, and moderate chronic renal insufficiency. The patient was treated with dabigatran for a left ventricular aneurysm with thrombus. Cutaneous manifestation of a voluminous haematoma required emergency surgery. Blood tests revealed dabigatran anticoagulant activity of 123 ng ml(1) (therapeutic values: 85200 ng ml(1)), activated partial thromboplastin time of 63 s, and a prothrombin ratio of 68, indicating that dabigatran disturbed coagulation. We decided to perform emergency haemodialysis before surgery. After 2 h, the anticoagulant activity of dabigatran was 11 ng ml(1), allowing surgery. Surgery proceeded without any problems and the postoperative period was unremarkable. This case highlights the difficulties for the anaesthesiologist regarding emergency perioperative management of patients treated with NOAs and confirms the efficacy of haemodialysis in cases of dabigatran treatment. NOAs should be prescribed with caution, especially for patients with renal or hepatic disease, at least as long as no antagonist is available. In cases of deferred operative urgency in haemodynamically stable patients treated with dabigatran, haemodialysis should be considered to reverse dabigatrans anticoagulant effects.
引用
收藏
页码:776 / 777
页数:2
相关论文
共 10 条
[1]   Hemorrhagic complications associated with dabigatran use [J].
Chen, Betty C. ;
Viny, Aaron D. ;
Garlich, Fiona M. ;
Basciano, Paul ;
Howland, Mary Ann ;
Smith, Silas W. ;
Hoffman, Robert S. ;
Nelson, Lewis S. .
CLINICAL TOXICOLOGY, 2012, 50 (09) :854-857
[2]   Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma [J].
Dumkow, Lisa E. ;
Voss, Johnathan R. ;
Peters, Michael ;
Jennings, Douglas L. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (19) :1646-1650
[3]   Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial [J].
Eriksson, Bengt I. ;
Dahl, Ola E. ;
Rosencher, Nadia ;
Kurth, Andreas A. ;
van Dijk, C. Niek ;
Frostick, Simon P. ;
Prins, Martin H. ;
Hettiarachchi, Rohan ;
Hantel, Stefan ;
Schnee, Janet ;
Bueller, Harry R. .
LANCET, 2007, 370 (9591) :949-956
[4]  
Harinstein LM, 2012, J PHARM PRACT
[5]   Reversal for heparins and new anticoagulant treatments [J].
Kortchinsky, T. ;
Vigue, B. ;
Samama, C. M. .
ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2013, 32 (01) :37-49
[6]   New anticoagulants: A concise review [J].
Kreuziger, Lisa M. Baumann ;
Morton, Colleen T. ;
Dries, David J. .
JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2012, 73 (04) :983-992
[7]   Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. [J].
Schulman, Sam ;
Kearon, Clive ;
Kakkar, Ajay K. ;
Mismetti, Patrick ;
Schellong, Sebastian ;
Eriksson, Henry ;
Baanstra, David ;
Schnee, Janet ;
Goldhaber, Samuel Z. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (24) :2342-2352
[8]   Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate An Open-Label, Parallel-Group, Single-Centre Study [J].
Stangier, Joachim ;
Rathgen, Karin ;
Stahle, Hildegard ;
Mazur, Dago .
CLINICAL PHARMACOKINETICS, 2010, 49 (04) :259-268
[9]  
Wanek Matthew R, 2012, Ann Pharmacother, V46, pe21, DOI 10.1345/aph.1R081
[10]   Factor Xa or thrombin: Is thrombin a better target? [J].
Weitz, J. I. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 :65-67